Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

BACKGROUND: Thymic malignancies are rare intrathoracic tumors, which may be aggressive and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic setting, with limited treatment options after the failure of first-line platinum-based chemotherapy. They are frequently as...

Descripción completa

Detalles Bibliográficos
Autores principales: Girard, N., Ponce Aix, S., Cedres, S., Berghmans, T., Burgers, S., Toffart, A.-C., Popat, S., Janssens, A., Gervais, R., Hochstenbag, M., Silva, M., Burger, I.A., Prosch, H., Stahel, R., Xenophontos, E., Pretzenbaher, Y., Neven, A., Peters, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265606/
https://www.ncbi.nlm.nih.gov/pubmed/37285717
http://dx.doi.org/10.1016/j.esmoop.2023.101576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265606/
https://www.ncbi.nlm.nih.gov/pubmed/37285717
http://dx.doi.org/10.1016/j.esmoop.2023.101576

Ejemplares similares